Only a few patients have undergone an intensive gene therapy cure for sickle cell disease since it was approved by the FDA ...

A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...

Novartis reported that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) reached its primary endpoint in a Phase III study in paediatric patients aged two to 17 with type II ...

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...

Healthcare stocks, especially biopharmaceuticals, are forecasted to outperform the market due to four key investment themes.

Regeneron Pharmaceuticals (NASDAQ:REGN), the maker of eye disease therapy Eylea, has acquired Oxular, a U.K.-based biotech drug developer focused on ophthalmology. While neither company formally ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

As we have entered into the new year 2025, here's a recap of 2024's economy and healthcare with key areas to look in global ...